What does APOTHEEK DE GAPER do?

APOTHEEK DE GAPER is a pharmacy in Mortsel. Public Limited, started on 13 December 1989, 1 establishment.

What is the address of APOTHEEK DE GAPER?

The registered office of APOTHEEK DE GAPER is located at Liersesteenweg 77, 2640 Mortsel.

Is APOTHEEK DE GAPER still active?

Yes. According to the CBE (30 October 2026) APOTHEEK DE GAPER is active, legal situation “Normale toestand”, started on 13 December 1989.

Is APOTHEEK DE GAPER registered on Peppol?

Yes, APOTHEEK DE GAPER is registered on the Peppol network with ID 0208:0439125433.

What is the enterprise number of APOTHEEK DE GAPER?

The enterprise number of APOTHEEK DE GAPER is BE0439125433.

When was APOTHEEK DE GAPER founded?

APOTHEEK DE GAPER was founded on 13 December 1989.

Who are the directors of APOTHEEK DE GAPER?

According to the 2025 annual accounts, the directors of APOTHEEK DE GAPER are: Peter Verbiest, Martine Desmet, Farmalex BV.

Is APOTHEEK DE GAPER a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 13 December 1989; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did APOTHEEK DE GAPER make in 2025?

APOTHEEK DE GAPER posted a profit after taxes of € 52,663 in financial year 2025.

What is the revenue of APOTHEEK DE GAPER?

As a small company, APOTHEEK DE GAPER is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 157,365.

How much does an employee at APOTHEEK DE GAPER earn?

The average wage cost per full-time employee at APOTHEEK DE GAPER was € 74,400 in 2025: staff costs of € 89,333 for 1.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does APOTHEEK DE GAPER have?

According to the 2025 annual accounts, APOTHEEK DE GAPER has 1.2 full-time equivalents (FTE).

Does APOTHEEK DE GAPER have a website?

Yes, APOTHEEK DE GAPER has a website at apotheekdegaper.be.

APOTHEEK DE GAPER (Public Limited) - Mortsel

Dossier APOTHEEK DE GAPER, printed on 30 October 2026 from databakkes.be/en/0439125433/apotheek-de-gaper. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

APOTHEEK DE GAPER from Mortsel, company number BE0439125433, closed financial year 2025 with a result of € 52,663 after tax. For that financial year APOTHEEK DE GAPER recorded a gross margin of € 157,365 and equity of € 129,064. Compared with financial year 2024, the result moved from € 58,434 to € 52,663. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.

What it is worth Growing

€ 129,064

▲ 69% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 52,663

▼ 10% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 31,433

▲ 64% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 46,019.

People and assets in 2025

Full-time equivalents

1.2

▼ 0.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 89,333

▲ 6% vs 2024

€ 74,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

€ 563

▼ 98% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 25,489

▼ 27% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 12,614

▲ 10% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 193,656 Gross margin 2022: € 193,656 First fiscal year in the series	€ 132,729 Gross margin 2023: € 132,729 ▼ 31% vs 2022 (€ 193,656) Unfavourable step	€ 186,623 Gross margin 2024: € 186,623 ▲ 41% vs 2023 (€ 132,729) Favourable step	€ 157,365 Gross margin 2025: € 157,365 ▼ 16% vs 2024 (€ 186,623) Unfavourable step	▼ 16%
Profit after taxes	€ 39,632 Profit after taxes 2022: € 39,632 First fiscal year in the series	€ -5,465 Profit after taxes 2023: € -5,465 ▼ € 45,097 vs 2022 (€ 39,632) Unfavourable step	€ 58,434 Profit after taxes 2024: € 58,434 ▲ € 63,899 vs 2023 (€ -5,465) Favourable step	€ 52,663 Profit after taxes 2025: € 52,663 ▼ 10% vs 2024 (€ 58,434) Unfavourable step	▼ 10%
Equity	€ 23,431 Equity 2022: € 23,431 First fiscal year in the series	€ 17,966 Equity 2023: € 17,966 ▼ 23% vs 2022 (€ 23,431) Unfavourable step	€ 76,400 Equity 2024: € 76,400 ▲ € 58,434 vs 2023 (€ 17,966) Favourable step	€ 129,064 Equity 2025: € 129,064 ▲ 69% vs 2024 (€ 76,400) Favourable step	▲ 69%
Total debts	€ 245,448 Total debts 2022: € 245,448 First fiscal year in the series	€ 242,358 Total debts 2023: € 242,358 ▼ 1% vs 2022 (€ 245,448) Favourable step	€ 146,937 Total debts 2024: € 146,937 ▼ 39% vs 2023 (€ 242,358) Favourable step	€ 99,043 Total debts 2025: € 99,043 ▼ 33% vs 2024 (€ 146,937) Favourable step	▼ 33%
Cash	€ 35,059 Cash 2022: € 35,059 First fiscal year in the series	€ 41,590 Cash 2023: € 41,590 ▲ 19% vs 2022 (€ 35,059) Favourable step	€ 19,216 Cash 2024: € 19,216 ▼ 54% vs 2023 (€ 41,590) Unfavourable step	€ 31,433 Cash 2025: € 31,433 ▲ 64% vs 2024 (€ 19,216) Favourable step	▲ 64%
Retained profit	€ -59,613 Retained profit 2022: € -59,613 First fiscal year in the series	€ -65,078 Retained profit 2023: € -65,078 ▼ € 5,465 vs 2022 (€ -59,613) Unfavourable step	€ -6,644 Retained profit 2024: € -6,644 ▲ € 58,434 vs 2023 (€ -65,078) Favourable step	€ 46,019 Retained profit 2025: € 46,019 ▲ € 52,663 vs 2024 (€ -6,644) Favourable step	▲ € 52,663
Bank debt	€ 104,575 Bank debt 2022: € 104,575 First fiscal year in the series	€ 86,107 Bank debt 2023: € 86,107 ▼ 18% vs 2022 (€ 104,575) Favourable step	€ 35,449 Bank debt 2024: € 35,449 ▼ 59% vs 2023 (€ 86,107) Favourable step	€ 563 Bank debt 2025: € 563 ▼ 98% vs 2024 (€ 35,449) Favourable step	▼ 98%
Balance sheet total	€ 268,879 Balance sheet total 2022: € 268,879 First fiscal year in the series	€ 260,325 Balance sheet total 2023: € 260,325 ▼ 3% vs 2022 (€ 268,879) Unchanged	€ 223,337 Balance sheet total 2024: € 223,337 ▼ 14% vs 2023 (€ 260,325) Unchanged	€ 228,107 Balance sheet total 2025: € 228,107 ▲ 2% vs 2024 (€ 223,337) Unchanged	▲ 2%
Employees (FTE)	1.7 Employees (FTE) 2022: 1.7 First fiscal year in the series	1.4 Employees (FTE) 2023: 1.4 ▼ 0.3 vs 2022 (1.7) Unchanged	1.4 Employees (FTE) 2024: 1.4 Unchanged (1.4) Unchanged	1.2 Employees (FTE) 2025: 1.2 ▼ 0.2 vs 2024 (1.4) Unchanged	▼ 0.2

Key figures of APOTHEEK DE GAPER, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to APOTHEEK DE GAPER?

What happened at APOTHEEK DE GAPER in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 30, 2026 New annual accounts for financial year 2025: profit of € 52,663 (▼ 10% vs 2024). Source: NBB ↗
2011 Peter Verbiest became a director. NBB
2011 Martine Desmet became a director. NBB
2011 Farmalex BV became a director. NBB
Jan 10, 1990 New establishment in Mortsel. KBO
Dec 13, 1989 Start of the company according to the CBE. KBO

In short

From € 39,632 profit in 2022 to € 52,663 profit in 2025.

Best year ever: 2024, with € 58,434 profit.

On average € 131,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

FARMALEX 100%

The stake of FARMALEX comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

APOTHEEK DE GAPER

Behind APOTHEEK DE GAPER are Peter Verbiest, Martine Desmet and Farmalex BV. The shares are held by FARMALEX (100%).

Directors

According to the 2025 annual accounts

Peter Verbiest

Bestuurder

since 2011

Martine Desmet

Bestuurder

since 2011

Farmalex BV

Gedelegeerd bestuurder · represented by Peter Verbiest

since 2011

Shareholders

FARMALEX

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Liersesteenweg 77

2640 Mortsel

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS apotheekdegaper.be

Canonical: https://www.apotheekdegaper.be

Technologies

ASP.NETAdvanced Custom FieldsGoogle App EngineLodashPWAReactWixlazysizes

Hosting & Email

Email provider

Microsoft 365

Hosting

GOOGLE-CLOUD-PLATFORM - Google LLC, US

Website info

HTTPS Ja

Languages NL

Features

Webshop

Security

✓ HTTPS

✓ SPF

✗ DMARC

Details

Company number

0439.125.433

VAT number

BE 0439.125.433

Registered office

Liersesteenweg 77, 2640 Mortsel

Names & denominations

APOTHEEK DE GAPER

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

13 December 1989

Peppol

Active · Active since 24 Nov 2023

Contact

apotheekdegaper.be +32 3 449 48 78

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

APOTHEEK DE GAPER

Financials

What happened to APOTHEEK DE GAPER?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Website

Technologies

Hosting & Email

Website info

Features

Security

Details

Frequently asked questions